Metastatic Prostate Cancer- Pipeline Insight, 2024

Metastatic Prostate Cancer- Pipeline Insight, 2024

DelveInsight’s, “Metastatic Prostate Cancer- Pipeline Insight, 2024” report provides comprehensive insights about 95+ companies and 100+ pipeline drugs in Metastatic Prostate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Metastatic Prostate Cancer: Understanding

Metastatic Prostate Cancer: Overview

Metastatic Prostate Cancer refers to the cancer that has spread from the prostate to other parts of the body. It is sometimes called advanced prostate cancer. It most commonly spreads to lymph nodes in other parts of the body or to the bones. It can also spread to other organs such as the lungs. Metastatic prostate cancers show higher levels of active β1 integrin, which confers both an enhanced capacity to colonize distant organs, through the adhesion to ECM molecules like fibronectin and collagen type I, and a survival advantage, through an increase in the resistance to anoikis—the programmed cell death induced by insufficient adhesion to the growth substrate.

Common symptoms of metastatic prostate cancer includes, bone pain and broken bones for no reason, trouble urinating or decreased force of urine stream, blood in the urine or semen, tiredness/fatigue, swollen breasts, depression, memory loss, and heart problems, unexplained weight loss, erectile dysfunction, unexplained fevers, etc.

The treatment options for metastatic prostate cancer include chemotherapy, hormone therapy, and immunotherapy. Chemotherapy, such as docetaxel, is a common treatment for metastatic prostate cancer, often used in combination with hormone therapy. Hormone therapy works by slowing or blocking the growth of prostate cancer cells by reducing testosterone levels. Immunotherapy, specifically sipuleucel-T, has been approved by the FDA for advanced metastatic prostate cancer, utilizing the immune system to target cancer cells. Additionally, checkpoint inhibitors have been investigated as a type of immunotherapy for prostate cancer treatment. These treatment options aim to reduce symptoms, improve quality of life, and help patients live longer with metastatic prostate cancer.

Prostate cancer is staged using the TNM system, which considers the size and extent of the primary tumor (T), whether it has spread to nearby lymph nodes (N), and whether it has metastasized to distant sites (M). Early-stage prostate cancer is localized to the prostate gland (Stage I-II), while locally advanced disease (Stage III) indicates the tumor has grown outside the prostate. Metastatic prostate cancer (Stage IV) has spread to distant organs or lymph nodes. Factors like PSA levels, tumor grade, and extent of spread are used to further categorize prostate cancer into risk groups, which help guide treatment decisions. Overall, prostate cancer has a high 5-year survival rate, especially when detected and treated early.

""Metastatic Prostate Cancer- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metastatic Prostate Cancer pipeline landscape is provided which includes the disease overview and Metastatic Prostate Cancer treatment guidelines. The assessment part of the report embraces, in depth Metastatic Prostate Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Prostate Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Prostate Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Metastatic Prostate Cancer.

Metastatic Prostate Cancer Emerging Drugs Chapters

This segment of the Metastatic Prostate Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Metastatic Prostate Cancer Emerging Drugs

Saruparib: AstraZeneca

Saruparib is a poly-ADP ribose polymerase 1 (PARP1) specific inhibitor, which showed promising tumor growth inhibition in preclinical models of breast, ovarian, pancreatic, and prostate cancer harboring HRR deficiency mutations. Because the drug was less toxic than other PARP inhibitors, it could be given at higher doses. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients suffering from metastatic prostate cancer.

Onvansertib: Cardiff Oncology

Onvansertib is a first-in-class, third-generation, oral and highly-selective adenosine triphosphate (ATP) competitive inhibitor of the serine/threonine polo-like-kinase 1 (PLK1) enzyme, which is over-expressed in multiple cancers including leukemias, lymphomas and solid tumors. Onvansertib targets the PLK1 isoform only (not PLK2 or PLK3), is orally administered and has a 24-hour half-life with only mild-to-moderate side effects reported. The drug is currently being evaluated under Phase II clinical trial for the treatment of prostate cancer.

ONCT-534: Oncternal Therapeutics

ONCT-534, Dual-Action Androgen Receptor Inhibitor (DAARI) candidate, is a novel investigational, potentially first-in-class, orally bioavailable, dual-action androgen receptor (AR) inhibitor, designed to treat patients with metastatic castration-resistant prostate cancer and other androgen receptor-driven diseases. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of metastatic prostate cancer.

VIO-01: Valerio Therapeutics

VIO-01 is designed to abrogate several DNA repair pathways and trigger a robust immune response by activating the innate immune response through the STING pathway. The STING pathway plays a critical role in detecting DNA abnormalities and activating the immune system to target and destroy cancer cells. VIO-01 is currently undergoing proof-of-concept IND-enabling preclinical studies, alone and in combination with cancer immunotherapies. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of metastatic prostate cancer.

ORIC-944: ORIC Pharmaceuticals

ORIC-944 is a potent, orally bioavailable, highly selective allosteric small molecule inhibitor of PRC2, the complex which tri-methylates histone H3 lysine 27 (H3K27me3) via targeting the embryonic ectoderm development (EED) subunit. The drug is currently being evaluated under Phase I clinical trial for the treatment of prostate cancer.

Further product details are provided in the report……..

Metastatic Prostate Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Metastatic Prostate Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Metastatic Prostate Cancer

There are approx. 95+ key companies which are developing the therapies for Metastatic Prostate Cancer. The companies which have their Metastatic Prostate Cancer drug candidates in the most advanced stage, i.e. Phase III include, AstraZeneca.

Phases

DelveInsight’s report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Metastatic Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous

Subcutaneous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal antibody

Small molecule

Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Metastatic Prostate Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Metastatic Prostate Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic Prostate Cancer drugs.

Metastatic Prostate Cancer Report Insights

Metastatic Prostate Cancer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Metastatic Prostate Cancer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Metastatic Prostate Cancer drugs?

How many Metastatic Prostate Cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Metastatic Prostate Cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Metastatic Prostate Cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Metastatic Prostate Cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

AstraZeneca

Cardiff Oncology

Oncternal Therapeutics

Valerio Therapeutics

ORIC Pharmaceuticals

Astellas Pharma

MediLink Therapeutics

Sagimet Biosciences

Genentech

Regeneron Pharmaceuticals

Pfizer

Orion Pharma

Allarity Therapeutics

Janssen Research & Development

Key Products

Saruparib

Onvansertib

ONCT-534

VIO-01

ORIC-944

ZEN003694

YL201

TVB-2640

RO7656594

REGN5678

PF-07248144

ODM-209

LiPlaCis

JNJ-78278343

Please Note: It will take 3-5 business days to complete the report upon order confirmation.